drugset / Trial / NCT05176509
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2022-04-05
- Primary completion
- 2023-08-23
- Completion
- 2023-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | YH001 | Unknown | — | Intravenous |
| Subject | YH003 | Unknown | — | Intravenous |